Predictors of the Outcome at 2 Years in Neonates With Congenital Cytomegalovirus Infection

Jacques Fourgeaud,Jean-François Magny,Sophie Couderc,Patricia Garcia,Anne-Marie Maillotte,Melinda Benard,Didier Pinquier,Philippe Minodier,Dominique Astruc,Hugues Patural,Sophie Parat,Bernard Guillois,Armelle Garenne,Tiffany Guilleminot,Marine Parodi,Laurence Bussières,Idir Ghout,Yves Ville,Marianne Leruez-Ville
DOI: https://doi.org/10.1542/peds.2023-063531
2024-03-15
PEDIATRICS
Abstract:BACKGROUND Approximately 20% of neonates with congenital cytomegalovirus (cCMV) develop long-term sequelae. The ability to accurately predict long-term outcomes as early as the neonatal period would help to provide for appropriate parental counseling and treatment indications. With this study, we aimed to identify neonatal predictive markers of cCMV long-term outcomes. METHODS As this study’s subjects, we chose neonates diagnosed with cCMV in 13 hospitals throughout France recruited from 2013 to 2017 and evaluated for at least 2 years with thorough clinical, audiology, and imaging evaluations and psychomotor development tests. RESULTS A total of 253 neonates were included, and 3 were later excluded because of the identification of a genetic disorder. A total of 227 were followed up for 2 years: 187/227 (82%) and 34/227 (15%) were infected after a maternal primary or nonprimary infection, respectively, 91/227 (40%) were symptomatic at birth, and 44/227 (19%) had cCMV sequelae. Maternal primary infection in the first trimester was the strongest prognosis factor (odds ratio = 38.34 [95% confidence interval, 5.02–293], P < .001). A predictive model of no risk of sequelae at 2 years of age according to normal hearing loss at birth, normal cerebral ultrasound, and normal platelet count had 98% specificity, 69% sensitivity, and 0.89 area under the curve (95% confidence interval, 0.83–0.96). CONCLUSIONS In the studied population, children with normal hearing at birth, normal platelet count at birth, and a normal cranial ultrasound had no risk of neurologic sequelae and a low risk of delayed unilateral sensorineural hearing loss. The use of this model based on readily available neonatal markers should help clinicians establish a personalized care pathway for each cCMV neonate.
pediatrics
What problem does this paper attempt to address?